Genomic-targeted therapy to EGFR gene mutations (TKI), EML4–ALK fusion and ROS1 translocations, have proven marked treatment responses being more effective than conventional chemotherapies in advanced NSCLC patients [3, 4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.